221 filings
Page 3 of 12
8-K
1899v0ndntyk6l yan
29 Mar 22
Departure of Directors or Certain Officers
4:31pm
8-K
uuem8y82mrr idzi
24 Mar 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:31pm
POS AM
ysp6fd4dels10 kf909
22 Mar 22
Prospectus update (post-effective amendment)
4:30pm
POSASR
xb0hs4p spynwm5pce5y
16 Mar 22
Automatic shelf registration (post-effective amendment)
5:21pm
8-K
7461u5a9l96uwoig 3o
16 Mar 22
Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
5:18pm
8-K
dc3yatptemvg3q9 l4l
22 Feb 22
Athenex Announces Appointment of Chief Financial Officer
4:16pm
8-K
koiucbsxgs0e ca
15 Feb 22
Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility
9:00am
8-K
580lfqx
21 Jan 22
Entry into a Material Definitive Agreement
4:16pm
8-K
mrjgiqpw9kfq 1954nu
12 Jan 22
Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility
8:36am
8-K
w3kl3
28 Dec 21
Departure of Directors or Certain Officers
4:16pm
8-K
cqu pa1xl
4 Nov 21
Athenex Provides Third Quarter 2021 Corporate and Financial Update
7:05am
8-K
iiv6h77gg8k12jbk07gq
12 Oct 21
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer
6:31am
8-K
q4q7ib1b148 3t8
3 Sep 21
Departure of Directors or Certain Officers
7:16am
8-K
adhh7mbcm9 46
20 Aug 21
Entry into a Material Definitive Agreement
5:20pm
424B5
df6ktw3p
20 Aug 21
Prospectus supplement for primary offering
5:19pm
424B5
tthyfmatk8yy
16 Aug 21
Prospectus supplement for primary offering
5:27pm
EFFECT
je9g6jmn91x
13 Aug 21
Notice of effectiveness
12:15am
CORRESP
pkom6lvss0m
10 Aug 21
Correspondence with SEC
12:00am